Bradycor bradykinin antagonist: Completed a Phase II trial

Cortech Inc. (CRTQ), Denver Product: Bradycor bradykinin antagonist Indication: Systemic inflammatory response syndrome (SIRS) and suspected sepsis Status: Completed enrollment of 500 patients in a Ph...